SGLT2
15 drugs MetabolicCardiovascular
5
approved indications
15
Approved Drugs
6
Companies
11
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 15 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (11 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Boehringer Ingelheim 5 drugs
Johnson & Johnson 3 drugs
Merck 3 drugs
By Therapeutic Area
Metabolic 11 drugs
Cardiovascular 2 drugs
Drugs by Company PRO
Boehringer Ingelheim 5 drugs
Johnson & Johnson 3 drugs
Merck 3 drugs
LEXICON PHARMS INC 1 drug
THERACOSBIO 1 drug
By Therapeutic Area
Metabolic 11 drugs
INVOKAMET, INVOKAMET XR, XIGDUO XR, SYNJARDY XR +7 more
Cardiovascular 2 drugs
FARXIGA, INPEFA
Other 2 drugs
INVOKANA, STEGLATRO
Indications Treated
Type 2 DiabetesChronic Kidney DiseaseHeart FailureType 2 diabetes mellitusCardiovascular DiseaseKidney DiseaseDiabetic NephropathyGlycemic control in adults with type 2 diabetes mellitusMajor adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular diseaseEnd-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuriaEnd-Stage Kidney Disease
All Drugs Targeting SGLT2
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| INVOKAMET | Johnson & Johnson | 2014 | 5 | Metabolic |
| INVOKAMET XR | Johnson & Johnson | 2016 | 4 | Metabolic |
| FARXIGA | AstraZeneca | 2014 | 3 | Cardiovascular |
| INPEFA | LEXICON PHARMS INC | 2023 | 3 | Cardiovascular |
| INVOKANA | Johnson & Johnson | 2013 | 3 | |
| XIGDUO XR | AstraZeneca | 2014 | 3 | Metabolic |
| SYNJARDY XR | Boehringer Ingelheim | 2016 | 3 | Metabolic |
| JARDIANCE | Boehringer Ingelheim | 2014 | 3 | Metabolic |
| SYNJARDY | Boehringer Ingelheim | 2015 | 3 | Metabolic |
| GLYXAMBI | Boehringer Ingelheim | 2015 | 1 | Metabolic |
| STEGLATRO | Merck | 2017 | 1 | |
| TRIJARDY XR | Boehringer Ingelheim | 2020 | 1 | Metabolic |
| STEGLUJAN | Merck | 2017 | 1 | Metabolic |
| BRENZAVVY | THERACOSBIO | 2023 | 1 | Metabolic |
| SEGLUROMET | Merck | 2017 | 1 | Metabolic |